Bristol-Myers Squibb (BMY) Presents Strong Data from Opdivo + Yervoy Combo Phase 1 in mRCC

Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer

Updated data from CheckMate -057 and -017 show Opdivo-treated patients had tripled the duration of response compared to those treated with docetaxel, with a minimum follow-up of two years

In CheckMate -057, durable responses and complete responses were observed with Opdivo in both PD-L1 expressors and non-expressors

Patient-reported outcomes from CheckMate -057 show favorable overall health status with Opdivo versus docetaxel in previously treated advanced non-small cell lung cancer patients

PRINCETON, N.J.--(BUSINESS WIRE)--... More

Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress

The combination of lirilumab and nivolumab in a phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy;

Data supports ongoing Phase I cohort expansion of lirilumab in combination with nivolumab;

Efficacy data will be presented at the Society for Immunotherapy of Cancer 2016 conference

PRINCETON, N.J. and MARSEILLE, France, Oct. 9, 2016 (GLOBE NEWSWIRE) --... More

Updated Results Presented for the Opdivo (nivolumab) and Yervoy (ipilimumab) Combination in Metastatic Renal Cell Carcinoma From Phase 1 Study

Durable responses observed with the Opdivo and Yervoy combination in an updated analysis of CheckMate -016

Confirmed objective response rate for both combination regimen cohorts was 40.4%

The safety profile of the Opdivo and Yervoy combination in metastatic renal cell carcinoma patients is consistent with previous reports of the regimen in other studies

PRINCETON, N.J.--(BUSINESS WIRE)--... More

Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress

The combination of lirilumab and nivolumab in a Phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy;

Data supports ongoing Phase I cohort expansion of lirilumab in combination with nivolumab;

Efficacy data will be presented at the Society for Immunotherapy of Cancer 2016 conference.

PRINCETON, N.J., & MARSEILLE, France--(BUSINESS WIRE)--... More

Opdivo (nivolumab) Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study

Opdivo-treated patients exhibited stable functioning and symptoms, whereas those treated with investigators choice of therapy exhibited statistically significant worsening of these outcomes

Opdivo more than doubled the time to deterioration for most functional domains

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) announced today new patient-reported... More

Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advance

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) announced today the final primary analysis of CheckMate -026, a trial investigating the use of Opdivo (nivolumab) monotherapy as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors expressed PD-L1 1%. The study was powered to assess progression-free survival (PFS) for patients with 5% PD-L1 expression. The topline results from this study were previously disclosed and showed CheckMate -026 did not meet the primary endpoint of superior PFS compared to chemotherapy. In... More